Serum to hold 15% in Biocon arm Biocon Biologics as part of a broad alliance that expects to leverage the partners' strengths and resources in vaccines and biologics. Pursuing opportunities based on the hot mRNA technology platform appears firmly on the table.
Biocon, Ltd. and the Serum Institute of India Pvt. Ltd. are combining forces in a multi-pronged alliance spanning vaccines and also antibodies targeting several infectious diseases as they seek to build scale in these businesses and have a significant impact globally, particularly across emerging markets.
Both partners also refer to the promise of mRNA technology and see this as a “very important opportunity” for the...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
